# Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

> **NCT05256225** · PHASE3 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 360 (estimated)

## Conditions studied

- Endometrial Carcinoma
- Endometrial Clear Cell Adenocarcinoma
- Endometrial Dedifferentiated Carcinoma
- Endometrial Endometrioid Adenocarcinoma
- Endometrial Mixed Cell Adenocarcinoma
- Endometrial Serous Adenocarcinoma
- Endometrial Undifferentiated Carcinoma
- Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Carboplatin
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Echocardiography Test
- **RADIATION:** High-Dose-Rate Vaginal Cuff Brachytherapy
- **DRUG:** Hyaluronidase-zzxf/Pertuzumab/Trastuzumab
- **PROCEDURE:** Multigated Acquisition Scan
- **DRUG:** Paclitaxel
- **OTHER:** Survey Administration
- **DRUG:** Trastuzumab/Hyaluronidase-oysk

## Key facts

- **NCT ID:** NCT05256225
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-16
- **Primary completion:** 2027-10-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05256225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05256225, "Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05256225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*